KQKai Qu

Kai Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kai Qu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Study on Mechanism of Huangqi-Shanyao-Danshen Compatibility in Treatment of Diabetic Nephropathy Based on GEO Database and Network Pharmacology and Molecular Docking

    by Xiaoqi Li, Kai Qu, Xia Shen, Xiancheng Li, Xiaoyong Yu

    To explore the significance of Huangqi in the treatment of DN, this article explored the potential targets and signaling pathways of Astragalus-Chinese yam-Salvia miltiorrhiza in the intervention of diabetic nephropathy (DN), based on GEO database combined with network pharmacology and molecular docking. The relevant chips of DN were searched by GEO database, and the chemical active substances and corresponding targets in Astragali Radix, Dioscoreae Rhizoma and Salviae Miltiorrhizae Radix et Rhizoma were screened by TCMSP database, and the intersection with differentially expressed genes was taken. Then, the PPI network diagram was constructed by String database and Cytoscape 3.9.0 software respectively, and the gene GO and KEGG enrichment analysis were carried out by R language, and the above research results were verified by molecular docking. The results of molecular docking showed that the receptors IL6 and IL1 B could stably bind and interact with quercetin, diosgenin and luteolin. Thus, the active components such as quercetin, luteolin and diosgenin of Astragalus-Dioscorea-Salvia miltiorrhiza play a therapeutic role in DN by acting on IL6, IL1 B, MM9 and other targets, regulating AGE-RAGE and other signaling pathways.

  • Open Access

    CDC20, A Hypermethylated Gene in Senescent Cells, is Associated with Hepatocellular Carcinoma Prognosis

    by Xiang Xianhong, Yunong Fu, Xing Zhang, Runchen Miao, Xiaohua Ma, Chang Liu, Kai Qu

    BackgroundHepatocellular carcinoma (HCC) is a malignancy with poor outcome. As an anti-tumor mechanism, the methylation pattern of gene in senescent cells is different from that in malignant ones deriving from physically senescent cells. Therefore, it is possible that aberrantly methylated senescence-associated genes could predict the prognosis of HCC patients.MethodsDifferentially expressed genes with aberrant methylation were explored in two senescent cell datasets and were selected as senescence-associated genes (SAGs). And we used the proliferation, cell cycle, and senescence β-galactosidase assay to detect the effects of downregulated CDC20, a SAG, on cell cycle arrest and cellular senescence. Then, we investigated the relationship between the expression and methylation of CDC20 in senescent and proliferating HCC cells which was treated by 5-Azacytidine demethylation and in HCC patients from The Cancer Genome Atlas database. Also, we combined the methylation and expression levels of CDC20 to evaluate the prognosis of CDC20. Finally, pyrophosphate sequencing was performed to validate the different methylation of CDC20.ResultsWe found one of 49 SAGs, named cell division cycle 20 (CDC20), to be downregulated with hypermethylation in senescent HCC cells but upregulated with hypomethylation in proliferating HCC cells. Then, restoration of CDC20 expression was observed after demethylation treatment. Moreover, knockdown of CDC20 was found to induce cell cycle arrest and cellular senescence. Furthermore, the expression of CDC20 was found to be negatively correlated with its methylation, and hypomethylation of CDC20 was found to have a significantly shorter overall survival. Finally, pyrophosphate sequencing results showed that cg16147196 in CDC20 has a remarkably higher methylation level in senescent HCC cells than that in the proliferating HCC cells. ConclusionsIn conclusion, our study indicated that CDC20, a hypermethylated gene in senescent cells, could be considered as an alternative prognostic marker in HCC.

  • Open Access

    Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection

    by Xiaohua Ma, Jingxian Gu, Kun Wang, Xing Zhang, Juan Bai, Jingyao Zhang, Chang Liu, Qiang Qiu, Kai Qu

    Hepatocellular carcinoma (HCC) remains a severe health issue worldwide, especially in Asia. To date, molecular classifications proposed for the overall survival (OS) or recurrence-free survival (RFS) prediction of Asian HCC patients after hepatectomy are quite few and limited in clinical practice. Here, we established a molecular subtyping system for Asian HCC to facilitate prognosis evaluation. Firstly, differentially expressed genes (DEGs) (FDR [false discovery rate] TP53 mutation. Furthermore, integration of the molecular subtype and TNM stage was demonstrated to improve risk stratification. Taken together, our molecular subtyping system exhibited great utility and potential in prognosis prediction and therapeutic decision making of Asian HCC patients.


  • Open Access

    IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma

    by Xing Zhang, Runchen Miao, Tian Liu, Xiaohong Xiang, Jingxian Gu, Yifan Jia, Zeyu Li, Yunong Fu, Yang He, Yuhua Zhang, et al.


  • Open Access

    Seven-senescence-associated gene signature predicts overall survival for Asian patients with hepatocellular carcinoma

    by Xiao-Hong Xiang, Li Yang, Xing Zhang, Xiao-Hua Ma, Run-Chen Miao, Jing-Xian Gu, Yu-Nong Fu, Qing Yao, Jing-Yao Zhang, Chang Liu, et al.

    Cellular senescence is a recognized barrier for progression of chronic liver diseases to hepatocellular carcinoma (HCC). The expression of a cluster of genes is altered in response to environmental factors during senescence. However, it is questionable whether these genes could serve as biomarkers for HCC patients. To develop a signature of senescence-associated genes (SAGs) that predicts patients' overall survival (OS) to improve prognosis prediction of HCC. SAGs were identified using two senescent cell models. Univariate COX regression analysis was performed to screen the candidate genes significantly associated with OS of HCC in a discovery cohort (GSE14520) for the least absolute shrinkage and selection operator modelling. Prognostic value of this seven-gene signature was evaluated using two independent cohorts retrieved from the GEO (GSE14520) and the Cancer Genome Atlas datasets, respectively. Time-dependent receiver operating characteristic (ROC) curve analysis was conducted to compare the predictive accuracy of the seven-SAG signature and serum α-fetoprotein (AFP). A total of 42 SAGs were screened and seven of them, including KIF18B, CEP55, CIT, MCM7, CDC45, EZH2, and MCM5, were used to construct a prognostic formula. All seven genes were significantly downregulated in senescent cells and upregulated in HCC tissues. Survival analysis indicated that our seven-SAG signature was strongly associated with OS, especially in Asian populations, both in discovery and validation cohorts. Moreover, time-dependent ROC curve analysis suggested the seven-gene signature had a better predictive accuracy than serum AFP in predicting HCC patients' 1-, 3-, and 5-year OS. We developed a seven-SAG signature, which could predict OS of Asian HCC patients. This risk model provides new clinical evidence for the accurate diagnosis and targeted treatment of HCC.


  • Open Access

    Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma

    by Jing-Xian Gu, Xing Zhang, Run-Chen Miao, Xiao-Hong Xiang, Yu-Nong Fu, Jing-Yao Zhang, Chang Liu, Kai Qu

    Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma


  • A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma

    by Jingxian Gu, Xing Zhang, Runchen Miao, Xiaohua Ma, Xiaohong Xiang, Yunong Fu, Chang Liu, Wenquan Niu, Kai Qu

    Growing evidence indicates that long non-coding RNAs (lncRNAs) may be potential biomarkers and therapeutic targets for many disease conditions, including cancer. In this study, we constructed a risk score system of three lncRNAs (LOC101927051, LINC00667 and NSUN5P2) for predicting the prognosis of small hepatocellular carcinoma (sHCC) (maximum tumor diameter ≤5 cm). The prognostic value of this sHCC risk model was confirmed in TCGA HCC samples (TNM stage I and II). Stratified survival analysis revealed that the suitable patient groups of the sHCC lncRNA-signature included HBV-infected and cirrhotic patients with better physical conditions yet lower levels of albumin and higher levels of alpha-fetoprotein preoperatively. Besides, Asian patients with no family history of HCC or history of alcohol consumption can be predicted more precisely. Molecular functional analysis indicated that PYK2 pathway was significantly enriched in the high-risk patients. Pathway enrichment analysis indicated that the two lncRNAs (LINC00667 and NSUN5P2) associated with poor prognosis were closely related to cell cycle. The nomogram based on the lncRNA-signature for RFS prediction in sHCC patients exhibited good performance in recurrence risk stratification. In conclusion, we identified a novel three-lncRNA-expression-based risk model for predicting the prognosis of sHCC.


  • Open Access

    Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation

    by Kai Qu, Xing Zhang, Ting Lin, Tian Liu, Zhixin Wang, Sushun Liu, Lei Zhou, Jichao Wei, Hulin Chang, Ke Li, et al.

    Pancreatic cancer (PC) is a highly fatal disease worldwide and is often misdiagnosed in its early stages. The exploration of novel non-invasive biomarkers will definitely benefit PC patients. Recently, circulating miRNAs in body fluids are emerging as non-invasive biomarkers for PC diagnosis. In this study, we first conducted comprehensive robust rank aggregation (RRA) analysis based on 21 published miRome profiling studies. We statistically identified and clinically validated a miRNA expression pattern in PC patients. These miRNAs consisted of four up-regulated (hsa-miR-21-5p, hsa-miR-31-5p, hsa-miR-210-3p and hsa-miR-155-5p) and three down-regulated miRNAs (hsa-miR-217, hsa-miR-148a-3p and hsa-miR-375). Among them, hsa-miR-21-5p was one of the most highly expressed miRNAs in the serum of PC patients. Our validation test further suggested a relatively high accuracy of serum hsa-miR-21-5p levels in the diagnosis of PC, with a sensitivity of 0.77 and a specificity of 0.80. Finally, a diagnostic meta-analysis based on 9 studies also revealed favorable sensitivity and specificity of circulating hsa-miR-21-5p for the diagnosis of PC (pooled sensitivity and specificity were 0.76 and 0.74, respectively), which was consistent with our findings. Taken together, as one of the most aberrantly expressed miRNAs in PC, circulating hsa-miR-21-5p might be a promising serum biomarker in patients with PC.


  • Open Access

    miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations

    by Yue Teng, Xuan Su, Xing Zhang, Yan Zhang, Chen Li, Wenquan Niu, Chang Liu, Kai Qu

    MiRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations